Taysha Gene Therapies ROA 2020-2026 | TSHA
Current and historical return on assets (ROA) values for Taysha Gene Therapies (TSHA) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Taysha Gene Therapies ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2026-03-31 | $-0.13B | $0.32B | -40.22% |
| 2025-12-31 | $-0.11B | $0.28B | -38.90% |
| 2025-09-30 | $-0.10B | $0.24B | -42.62% |
| 2025-06-30 | $-0.09B | $0.20B | -46.36% |
| 2025-03-31 | $-0.09B | $0.17B | -51.92% |
| 2024-12-31 | $-0.09B | $0.17B | -51.95% |
| 2024-09-30 | $-0.02B | $0.18B | -13.03% |
| 2024-06-30 | $-0.11B | $0.18B | -63.16% |
| 2024-03-31 | $-0.12B | $0.15B | -78.15% |
| 2023-12-31 | $-0.11B | $0.14B | -81.01% |
| 2023-09-30 | $-0.22B | $0.13B | -169.96% |
| 2023-06-30 | $-0.13B | $0.11B | -118.76% |
| 2023-03-31 | $-0.13B | $0.12B | -111.43% |
| 2022-12-31 | $-0.17B | $0.14B | -121.83% |
| 2022-09-30 | $-0.16B | $0.16B | -101.74% |
| 2022-06-30 | $-0.19B | $0.19B | -96.99% |
| 2022-03-31 | $-0.19B | $0.22B | -88.99% |
| 2021-12-31 | $-0.17B | $0.24B | -74.04% |
| 2021-09-30 | $-0.14B | $0.25B | -57.66% |
| 2021-06-30 | $-0.11B | $0.26B | -41.45% |
| 2021-03-31 | $-0.09B | $0.20B | -44.05% |
| 2020-12-31 | $-0.06B | $0.14B | -43.87% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $1.290B | $0.010B |
| Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |